Metabolic modulation: A new therapeutic target in treatment of heart failure

American Journal of Therapeutics

Volumn 18, Issue 6, 2011, Pages

  Palaniswamy, Chandrasekar ^a   Mellana, William Michael ^a   Selvaraj, Dhana R ^a   Mohan, Diwakar ^b  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

etomoxir; metabolic modulators; perhexiline; ranolazine; trimetazidine

Indexed keywords

ANTIANGINA PECTORIS AGENT; CARVEDILOL; ETOMOXIR; FATTY ACID; GLUCOSE; PERHEXILINE; PLACEBO; RANOLAZINE; TRIMETAZIDINE;

ADD ON THERAPY; ANGINA PECTORIS; ARTICLE; CELL PROTECTION; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG MECHANISM; FATTY ACID OXIDATION; GLUCOSE METABOLISM; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HEART PROTECTION; HUMAN; ISCHEMIC CARDIOMYOPATHY; KINESIOTHERAPY; LIVER TOXICITY; METABOLIC REGULATION; NONHUMAN; OXYGEN CONSUMPTION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACETANILIDES; CARNITINE O-PALMITOYLTRANSFERASE; ENZYME INHIBITORS; EPOXY COMPOUNDS; FATTY ACIDS; GLUCOSE; HEART FAILURE; HUMANS; MITOCHONDRIA, HEART; MYOCYTES, CARDIAC; PERHEXILINE; PIPERAZINES; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 81755184785     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181d70453     Document Type: Article

References (37)

1. Williams JF Jr, Bristow MR, Fowler MB, et al. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol. 1995;26:1376-1398.
2. Levit KR, Lazenby HC, Cown CA. National health expenditures, 1990. Health Care Fin Rev. 1991;13:29-54.
3. Graves EJ. National Hospital Discharge Survey: Annual Summary, 1993: Vital and Health Statistics, Series 13. Natl Health Surv. 1995;121:1-63.
4. Dyck JR, Lopaschuk GD. Malonyl CoA control of fatty acid oxidation in the ischemic heart. J Mol Cell Cardiol. 2002;34:1099-1109. (Pubitemid 35205154)
5. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res. 2000;86:580-588. (Pubitemid 30165050)
6. Fantini E, Demaison L, Sentex E, et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol. 1994;26:949-958. (Pubitemid 24279511)
7. Boucher FR, Hearse DJ, Opie LH. Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts. J Cardiovasc Pharmacol. 1994;24:45-49. (Pubitemid 24189598)
8. Ruixing Y,Wenwu L, Al-Ghazali R. Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia reperfusion. Transl Res. 2007;149:152-160. (Pubitemid 46275573)
9. Monti LD, Allibardi S, Piatti PM, et al. Triglycerides impair postischemic recovery in isolated rat hearts: roles of endothelin-1 and trimetazidine. Am J Physiol Heart Circ Physiol. 2001;281:1122-1130.
10. Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J. 1990;11:207-212. (Pubitemid 20119783)
11. Lu C, Dabrowski P, Fragasso G, et al. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol. 1998; 82:898-901. (Pubitemid 28467367)
12. Fragasso G, Piatti PM, Monti L, et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J. 2003;146:E18.
13. Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol. 2006;48:992-998. (Pubitemid 44292461)
14. Fragasso G, Perseghin G, DeCobelli F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J. 2006;27: 942-948.
15. Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation. 2008;118:1250-1258.
16. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J. 2001;22:2164-2170. (Pubitemid 33139462)
17. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45:469-491.
18. McCormack JG, Barr RL, Wolff AA, et al. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation. 1996;93:135-142. (Pubitemid 26007542)
19. Saint DA. The cardiac persistent sodium current: an appealing therapeutic target? Br J Pharmacol. 2008;153: 1133-1142. (Pubitemid 351415490)
20. Shryock JC, Belardinelli L. Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. Br J Pharmacol. 2008;153: 1128-1132. (Pubitemid 351415493)
21. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375-1382. (Pubitemid 38496341)
22. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309-316. (Pubitemid 38101603)
23. Chandler MP, Stanley WC, Morita H, et al. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res. 2002; 91:278-280. (Pubitemid 34976992)
24. Sabbah HN, Chandler MP, Mishima T, et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail. 2002;8:416-422. (Pubitemid 36055744)
25. Bouche P, Bousser MG, Peytour MA, et al. Perhexiline maleate and peripheral neuropathy. Neurology. 1979;29: 739-743. (Pubitemid 9135480)
26. Roberts RK, Cohn D, Petroff V, et al. Liver disease induced by perhexiline maleate. Med J Aust. 1981;2:553-554. (Pubitemid 12139318)
27. Morgan MY, Reshef R, Shah RR, et al. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut. 1984;25:1057-1064. (Pubitemid 14002119)
28. Horowitz JD, Sia ST, Macdonald PS, et al. Perhexiline maleate treatment for severe angina pectoriscorrelations with pharmacokinetics. Int J Cardiol. 1986; 13:219-229. (Pubitemid 16000586)
29. Cole PL, Beamer AD, McGowan N, et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation. 1990;81:1260-1270. (Pubitemid 20119624)
30. Kennedy JA, Kiosoglous AJ, Murphy GA, et al. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol. 2000;36:794-801.
31. Lee L, Campbell R, Scheuermann-Freestone M, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation. 2005;112:3280-3288. (Pubitemid 43739373)
32. Reaven GM, Chang H, Hoffman BB. Additive hypoglycemic effects of drugs that modify free-fatty acid metabolism by different mechanisms in rats with streptozocin-induced diabetes. Diabetes. 1988;37:28-32. (Pubitemid 18036453)
33. Lopaschuk GD, Wall SR, Olley PM, et al. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res. 1988;63: 1036-1043. (Pubitemid 19004258)
34. Vetter R, Rupp H. CPT-1 inhibition by etomoxir has a chamber-related action on cardiac sarcoplasmic reticulum and isomyosins. Am J Physiol. 1994;267: H2091-H209.
35. Zarain-Herzberg A, Rupp H, Elimban V, et al. Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir. FASEB J. 1996;10:1303-1309. (Pubitemid 26307516)
36. Turcani M, Rupp H. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation. 1997;96:3681-3686. (Pubitemid 27513449)
37. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond). 2000;99:27-35. (Pubitemid 30479390)